Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 4 Nov 2024

Kfoury Maria, Bonnet Clément, Delanoy Nicolas, Howarth Karen, Marzac Christophe, Rouleau Etienne, Micol Jean-Baptiste, Leary Alexandra

Abstract excerpt

There is a lack of biomarkers to predict outcome following initial treatment in patients with high-grade ovarian cancer. We hypothesized that monitoring TP53 mutation (TP53m) in circulating tumor DNA (ctDNA) could be a tumor-specific biomarker. Patients enrolled in a prospective study (NCT03010124) consented to analysis of biological samples through the disease course. ctDNA was extracted and analyzed to detect...

Topics

Join the communities discussing this publication.

Aged
Biomarkers, Tumor
Circulating Tumor DNA
TP53 gene
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Grading

Ovarian Neoplasms

Tumor Suppressor Protein p53

Source

Identifiers

PMID: 39313297
DOI: 10.1136/ijgc-2024-005581

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas.PMID 39313297Read ↗

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.Semantic proximity Read ↗

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.Semantic proximity Read ↗

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.Semantic proximity Read ↗

Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer.Semantic proximity Read ↗

Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysisSemantic proximity Read ↗

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic ImpactSemantic proximity Read ↗

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.Semantic proximity Read ↗

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Semantic proximity Read ↗

Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancerSemantic proximity Read ↗

Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.